(NASDAQ: EOLS) Evolus's forecast annual revenue growth rate of 25.26% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 37.62%, and while it is forecast to beat the US market's average forecast revenue growth rate of 21.94%.
Evolus's revenue in 2026 is $297,176,000.On average, 10 Wall Street analysts forecast EOLS's revenue for 2026 to be $22,120,396,600, with the lowest EOLS revenue forecast at $20,867,991,793, and the highest EOLS revenue forecast at $24,251,111,273. On average, 9 Wall Street analysts forecast EOLS's revenue for 2027 to be $25,873,056,823, with the lowest EOLS revenue forecast at $24,273,231,669, and the highest EOLS revenue forecast at $27,755,892,934.
In 2028, EOLS is forecast to generate $39,709,364,897 in revenue, with the lowest revenue forecast at $33,020,547,325 and the highest revenue forecast at $47,383,841,317.